Swedish Orphan Biovitrum Past Earnings Performance
Past criteria checks 1/6
Swedish Orphan Biovitrum's earnings have been declining at an average annual rate of -4.9%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 12.3% per year. Swedish Orphan Biovitrum's return on equity is 5.9%, and it has net margins of 9%.
Key information
-4.9%
Earnings growth rate
-6.9%
EPS growth rate
Biotechs Industry Growth | 0.7% |
Revenue growth rate | 12.3% |
Return on equity | 5.9% |
Net Margin | 9.0% |
Next Earnings Update | 24 Oct 2024 |
Recent past performance updates
Recent updates
Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 19Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly
Jun 24Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More
May 08Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 27Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Apr 24Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Apr 06Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly
Mar 05Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 15Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors
Jan 17Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Nov 24Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?
Jul 07Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Apr 02Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?
Jan 11These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well
Dec 27Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?
Sep 28Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?
Jun 26Swedish Orphan Biovitrum (STO:SOBI) Has A Somewhat Strained Balance Sheet
Mar 28Revenue & Expenses Breakdown
How Swedish Orphan Biovitrum makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 23,710 | 2,145 | 10,609 | 3,257 |
31 Mar 24 | 23,140 | 2,142 | 10,201 | 2,903 |
31 Dec 23 | 22,123 | 2,409 | 9,773 | 2,743 |
30 Sep 23 | 21,270 | 2,769 | 8,951 | 2,594 |
30 Jun 23 | 20,100 | 3,125 | 8,202 | 2,358 |
31 Mar 23 | 19,104 | 3,162 | 7,859 | 2,371 |
31 Dec 22 | 18,790 | 2,638 | 7,637 | 2,252 |
30 Sep 22 | 17,696 | 2,493 | 7,340 | 2,156 |
30 Jun 22 | 17,458 | 2,516 | 7,077 | 2,116 |
31 Mar 22 | 16,793 | 2,526 | 6,667 | 2,042 |
31 Dec 21 | 15,529 | 2,679 | 6,294 | 1,987 |
30 Sep 21 | 15,214 | 2,940 | 6,022 | 1,926 |
30 Jun 21 | 14,424 | 2,744 | 5,868 | 1,845 |
31 Mar 21 | 14,283 | 2,759 | 5,876 | 1,706 |
31 Dec 20 | 15,261 | 3,245 | 5,981 | 1,594 |
30 Sep 20 | 15,570 | 3,103 | 5,894 | 1,418 |
30 Jun 20 | 15,530 | 3,367 | 5,615 | 1,306 |
31 Mar 20 | 15,622 | 3,583 | 5,358 | 1,475 |
31 Dec 19 | 14,248 | 3,304 | 4,807 | 1,448 |
30 Sep 19 | 11,929 | 2,539 | 4,093 | 1,466 |
30 Jun 19 | 11,313 | 2,620 | 3,578 | 1,460 |
31 Mar 19 | 10,440 | 2,806 | 2,952 | 1,189 |
31 Dec 18 | 9,139 | 2,418 | 2,511 | 1,090 |
30 Sep 18 | 8,443 | 2,181 | 2,335 | 991 |
30 Jun 18 | 7,729 | 1,881 | 2,206 | 918 |
31 Mar 18 | 7,079 | 1,462 | 2,136 | 923 |
31 Dec 17 | 6,511 | 1,149 | 2,084 | 908 |
30 Sep 17 | 5,927 | 865 | 2,018 | 937 |
30 Jun 17 | 5,497 | 677 | 1,963 | 902 |
31 Mar 17 | 5,327 | 703 | 1,861 | 858 |
31 Dec 16 | 5,204 | 802 | 1,776 | 778 |
30 Sep 16 | 4,727 | 716 | 1,633 | 654 |
30 Jun 16 | 4,341 | 585 | 1,539 | 595 |
31 Mar 16 | 3,636 | 291 | 1,463 | 519 |
31 Dec 15 | 3,228 | 65 | 1,345 | 513 |
30 Sep 15 | 3,119 | 59 | 1,263 | 528 |
30 Jun 15 | 3,000 | 108 | 1,177 | 499 |
31 Mar 15 | 2,899 | 136 | 1,094 | 505 |
31 Dec 14 | 2,607 | -268 | 1,031 | 500 |
30 Sep 14 | 2,513 | -263 | 1,007 | 453 |
30 Jun 14 | 2,364 | -373 | 971 | 475 |
31 Mar 14 | 2,221 | -410 | 933 | 463 |
31 Dec 13 | 2,177 | -93 | 896 | 456 |
30 Sep 13 | 2,038 | -222 | 831 | 452 |
Quality Earnings: SOBI has high quality earnings.
Growing Profit Margin: SOBI's current net profit margins (9%) are lower than last year (15.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SOBI's earnings have declined by 4.9% per year over the past 5 years.
Accelerating Growth: SOBI's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SOBI had negative earnings growth (-31.4%) over the past year, making it difficult to compare to the Biotechs industry average (-13.6%).
Return on Equity
High ROE: SOBI's Return on Equity (5.9%) is considered low.